{'fraction_non_alphanumeric': 0.024769992922859165, 'fraction_numerical': 0.004953998584571833, 'mean_word_length': 5.3125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preparation and characterization of poly(L-lactic acid)-chitosan hybrid scaffolds with drug release capability.

Novel poly(L-lactic acid) (PLLA)-chitosan hybrid scaffolds were developed in order to be used as tissue-engineering scaffolds and drug release carriers. The incorporation of chitosan into the PLLA porous structure allows for producing chitosan-based scaffold devices with interesting damping and stiffness aimed at being used in tissue engineering of bone or cartilage. The pore structure of the hybrid scaffolds was influenced by the concentration of the chitosan solution introduced into the PLLA scaffold. For lower concentrations, chitosan was mainly deposited onto the PLLA surface, whereas for higher concentration chitosan formed also microfibrilar structures within the pore walls of the PLLA foam that may act as additional soft anchorage sites for cells. Equilibrium water uptakes up to about 110% were achieved in 24 h. An anti-inflammatory drug, ketoprofen, was loaded within the chitosan component of the hybrid scaffolds by immersing the scaffolds in a drug-ethanol solution. The drug was released sharply within the initial periods ( approximately 2-4 h), but the rate decreased further, showing a sustained release. The drug release rate can be controlled by the chitosan content and cross-link densities, suggesting the effectiveness of the hybrid scaffold as a drug delivery system.